All In Biotech

Drug Trial Radar · NCT00000599

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Last checked: Nov 20, 2026Latest source record: Dec 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

Not stated

Start

Jun 1980

Primary completion

Not stated

Study completion Nov 1994

Sponsor

Sponsor type
NIH
First posted
Oct 28, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Male only, from 40 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.

Conditions

  • Arterial Occlusive Diseases
  • Cardiovascular Diseases
  • Carotid Artery Diseases
  • Cerebral Arteriosclerosis
  • Cerebrovascular Disorders
  • Coronary Arteriosclerosis
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
  • Atherosclerosis

Interventions

  • colestipolDrug

  • niacinDrug

  • diet, fat-restrictedBehavioral

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.